OX17 combines two well-known substances that inhibit acid secretion in the stomach with different time to onset of effect – an H2-receptor blocker and a proton-pump inhibitor (PPI).
| Name |
OX17 |
| Active substances |
H2-receptor blocker and a proton-pump inhibitor (PPI) |
| Phase |
Phase II/III |
| Partner |
Novartis |
Market
IMS estimated that, in 2007, sales of H2-receptor antagonists amounted to USD 3bn and to more than USD 25bn for PPI.
Project status
In August 2009, Orexo signed a license agreement with Novartis in respect of OX17. Novartis is responsible for all continuing development costs.